Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
HLVX
Upturn stock ratingUpturn stock rating

Hillevax Inc (HLVX)

Upturn stock ratingUpturn stock rating
$1.61
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

03/27/2025: HLVX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -47.77%
Avg. Invested days 28
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 03/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 69.45M USD
Price to earnings Ratio -
1Y Target Price 2
Price to earnings Ratio -
1Y Target Price 2
Volume (30-day avg) 139901
Beta 0.75
52 Weeks Range 1.37 - 16.30
Updated Date 04/2/2025
52 Weeks Range 1.37 - 16.30
Updated Date 04/2/2025
Dividends yield (FY) -
Basic EPS (TTM) -3

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -24.89%
Return on Equity (TTM) -70.13%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -77473627
Price to Sales(TTM) -
Enterprise Value -77473627
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -4.07
Shares Outstanding 50141100
Shares Floating 30028884
Shares Outstanding 50141100
Shares Floating 30028884
Percent Insiders 16.99
Percent Institutions 72.21

Analyst Ratings

Rating 3
Target Price 3
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold 5
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Hillevax Inc

stock logo

Company Overview

overview logo History and Background

Hillevax, Inc. is a biopharmaceutical company focused on developing and commercializing novel vaccines. Founded in 2012, it achieved a significant milestone with the development of Vaxelis, a hexavalent combination vaccine. The company continues to innovate in the vaccine space, targeting unmet medical needs.

business area logo Core Business Areas

  • Vaccine Development: Research, development, and clinical trials for new vaccine candidates.
  • Commercialization: Manufacturing, marketing, and distribution of approved vaccines.

leadership logo Leadership and Structure

The leadership team consists of experienced executives in the pharmaceutical and biotech industries. The organizational structure includes research and development, clinical operations, commercial, and administrative functions.

Top Products and Market Share

overview logo Key Offerings

  • Vaxelis: A hexavalent combination vaccine protecting against diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b, and hepatitis B. Competitors include Sanofi's Pentacel and GSK's Infanrix Hexa. It is difficult to obtain precise market share data, but Vaxelis is a significant competitor in the hexavalent vaccine market, estimated at approximately $4 billion globally.

Market Dynamics

industry overview logo Industry Overview

The vaccine industry is characterized by increasing demand due to global health concerns and advancements in vaccine technology. Major players are continuously developing new vaccines and expanding their market presence.

Positioning

Hillevax is positioned as an innovator in the vaccine market, with a focus on combination vaccines. Its competitive advantage lies in its established product, Vaxelis and expertise in vaccine development and potential for expansion.

Total Addressable Market (TAM)

The global vaccine market is expected to reach approximately $100 billion by 2025. Hillevax is positioned to capture a portion of this market through its existing product and pipeline candidates.

Upturn SWOT Analysis

Strengths

  • Established product (Vaxelis)
  • Expertise in vaccine development
  • Strong research and development pipeline

Weaknesses

  • Reliance on a single key product
  • Competition from larger pharmaceutical companies
  • Limited marketing and distribution capabilities compared to larger competitors

Opportunities

  • Expansion into new markets
  • Development of new vaccine candidates
  • Partnerships with other pharmaceutical companies

Threats

  • Regulatory hurdles
  • Competition from established players
  • Patent expirations

Competitors and Market Share

competitor logo Key Competitors

  • SNY
  • GSK
  • MRK
  • PFE

Competitive Landscape

Hillevax faces intense competition from larger, more established pharmaceutical companies. Its success depends on its ability to innovate and effectively commercialize its products.

Major Acquisitions

Growth Trajectory and Initiatives

Historical Growth: Historical growth driven by the commercialization of Vaxelis.

Future Projections: Future growth dependent on the success of pipeline candidates and market expansion.

Recent Initiatives: Focus on expanding the market reach of Vaxelis and advancing pipeline candidates.

Summary

Hillevax is a growing biopharmaceutical company with a promising vaccine, Vaxelis, that is competing against larger more established players. It is working on new vaccine candidates to expand its portfolio. Hillevax needs to strengthen it's pipeline and expand its commercial reach. It must be cautious and handle the regulatory hurdles as well as the intense competition in the vaccine market.

Similar Companies

ABBVratingrating

AbbVie Inc

$176.9
Large-Cap Stock
0%
PASS

ABBVratingrating

AbbVie Inc

$176.9
Large-Cap Stock
0%
PASS

GSKratingrating

GlaxoSmithKline PLC ADR

$38.57
Large-Cap Stock
3.43%
Consider higher Upturn Star rating
BUY since 33 days

GSKratingrating

GlaxoSmithKline PLC ADR

$38.57
Large-Cap Stock
BUY since 33 days
3.43%
Consider higher Upturn Star rating

JNJratingrating

Johnson & Johnson

$153.25
Large-Cap Stock
1.05%
WEAK BUY
BUY since 43 days

JNJratingrating

Johnson & Johnson

$153.25
Large-Cap Stock
BUY since 43 days
1.05%
WEAK BUY

MRKratingrating

Merck & Company Inc

$87.12
Large-Cap Stock
0%
PASS

MRKratingrating

Merck & Company Inc

$87.12
Large-Cap Stock
0%
PASS

PFEratingrating

Pfizer Inc

$24.54
Large-Cap Stock
0%
PASS

PFEratingrating

Pfizer Inc

$24.54
Large-Cap Stock
0%
PASS

SNYratingrating

Sanofi ADR

$54.5
Large-Cap Stock
5.44%
Consider higher Upturn Star rating
BUY since 46 days

SNYratingrating

Sanofi ADR

$54.5
Large-Cap Stock
BUY since 46 days
5.44%
Consider higher Upturn Star rating

Sources and Disclaimers

Data Sources:

  • Company Website
  • Analyst Reports
  • Industry Reports

Disclaimers:

This analysis is based on publicly available information and does not constitute financial advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Hillevax Inc

Exchange NASDAQ
Headquaters Boston, MA, United States
IPO Launch date 2022-04-29
Co-Founder, President, CEO & Chairman of the Board Dr. Robert M. Hershberg M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 14
Full time employees 14

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​